Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Interest Expense - Debt (2021 - 2022)

Guided Therapeutics (GTHP) has disclosed Interest Expense - Debt for 2 consecutive years, with -$11503.0 as the latest value for Q2 2022.

  • Quarterly Interest Expense - Debt fell 200.0% to -$11503.0 in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $28094.0 through Jun 2022, changed N/A year-over-year, with the annual reading at $39597.0 for FY2022, 0.0% changed from the prior year.
  • Interest Expense - Debt hit -$11503.0 in Q2 2022 for Guided Therapeutics, down from $39597.0 in the prior quarter.
  • In the past five years, Interest Expense - Debt ranged from a high of $39597.0 in Q1 2022 to a low of -$11503.0 in Q2 2022.